Recursion Pharmaceuticals Inc (RXRX NASDAQ) stock market data APIs
$6.96
0.64(10.1%)
as of January 14, 2025
Recursion Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Prev. Close
6.32
Open
6.96
Volume
18 259 K
High
6.96
Low
6.2
52 wk Range
5.6-15.74
Market Cap
2 469 M
Shares Outstanding
384 M
Revenue
65 184 K
EPS
-0.34
Beta
0.802
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Recursion Pharmaceuticals Inc data using free add-ons & libraries
Get Recursion Pharmaceuticals Inc Fundamental Data
Recursion Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 65 184 K
- EBITDA: -364 150 016
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-06
- EPS/Forecast: -0.35
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Recursion Pharmaceuticals Inc News
New
Is Recursion Pharmaceuticals a Millionaire-Maker Stock?
In an environment where the typical small biotech name is riskier than not, this one is curiously different.
3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock
This company stands to benefit from a shifting pharmaceutical industry landscape.
Prediction: These 2 Stocks Could Soar in 2025
The key word here is "could."
Recursion Pharmaceuticals (RXRX) Stock Moves -0.74%: What You Should Know
In the latest market close, Recursion Pharmaceuticals (RXRX) reached $6.67, with a -0.74% movement compared to the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.76%....
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
